Navigation Links
Dana-Farber Cancer Institute's Ursula A. Matulonis, MD Article on EntreMed's ENMD-2076 Published in the European Journal of Cancer
Date:9/6/2012

ROCKVILLE, Md., Sept. 6, 2012 /PRNewswire/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, announced today the publication of an article by Ursula A. Matulonis, MD, of Dana-Farber Cancer Institute in Boston, entitled "ENMD-2076, an Oral Inhibitor of Angiogenic and Proliferation Kinases, Has Activity in Recurrent, Platinum Resistant Ovarian Cancer," in the European Journal of Cancer.

(Logo:  http://photos.prnewswire.com/prnh/20010620/ENMDLOGO )  

The article reports findings of a clinical trial providing evidence that ENMD-2076 has activity in platinum-resistant ovarian cancer, and observed toxicities were similar to other PO kinase inhibitors. Based on the findings, it is recommended that additional studies with ENMD-2076 are warranted, especially in combination with active chemotherapeutic agents in platinum-resistant patients.

The study which was an open-label single-arm Phase 2 study of a single agent ENMD-2076 taken daily orally (PO) had a total of 64 patients enrolled. The progression free survival rate (PFS) at 6 months was 22%, with a median time to progression of 3.6 months while median number of prior chemotherapy regimens was 2 months.  The other co-authors of the article include clinical investigators from Memorial Sloan-Kettering Cancer Center, Indiana University Simon Cancer Center, University of Colorado, and University of Chicago in the US as well as Princess Margaret Hospital and Campbell Family Institute for Cancer Research in Toronto, Canada.

Dr. Matulonis, who is the medical director of Gynecologic Oncology at Dana-Farber, commented on the publication, "Epithelial ovarian cancer represents the 4th leading cause of cancer deaths among women in the United Sta
'/>"/>

SOURCE EntreMed
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. ONCOLOGY and the Cancer Network Launch "Consultations in Ethics" Feature
2. ImaginAb and MacroGenics Collaborate to Develop In Vivo Imaging Agents for Autoimmune Diseases, Cancer
3. Leading Prostate Cancer Group Says New Drug Gives Hope To Men With Advanced Prostate Cancer
4. ThinkCure! Weekend At Dodger Stadium Expected To Raise Hundreds Of Thousands Of Dollars For Cancer Research
5. CyberKnife Cancer Institute of Chicago Is the First to Offer CyberKnife Treatment in the City of Chicago
6. Quest Diagnostics Launches Molecular Cervical Cancer Test Based on National Institutes of Healths TERC Gene Marker
7. Polymedco Aligns with MedPrimex to Fight Colorectal Cancer in Mexico
8. Janssen Biotech Announces Global License and Development Agreement for Investigational Anti-Cancer Agent Daratumumab
9. Esperance Pharmaceuticals Announces Completion of Run-in Enrollment of Phase 2 Study of EP-100 Plus Paclitaxel in Advanced Ovarian Cancer
10. Breast Cancer Diagnostic and Drug Technologies: Global Markets
11. Human Vaccines & Immunotherapeutics Special Focus Highlights a Paradigm Shift in Cancer Vaccine Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... BETHESDA, Md. , Jan. 23, 2015  Northwest Biotherapeutics, Inc. ... developing DCVax® personalized immune therapies for operable and inoperable solid ... will present at the 7 th Annual Phacilitate Immunotherapy ... NW Bio,s presentation at Phacilitate will take place on January ...
(Date:1/23/2015)... DUBLIN , Jan. 23, 2015  Immune Therapeutics, Inc. ... Biotechnology, Inc. for the compounding, packaging and distributing of its ... the United States . ... of compounding naltrexone tablets in various strengths for individual patients ...
(Date:1/23/2015)... , Jan. 23, 2015  HyGreen, Inc., a leader ... and partnership with RCA Medical, a subsidiary of Ascendis ... . Each year, hundreds of millions of ... infections as organisms are transmitted from patient to patient ...
Breaking Medicine Technology:NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 2NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 4HyGreen Partners with RCA Medical in Johannesburg, South Africa 2
(Date:1/22/2015)... Woodloch Pines, an all-inclusive family resort ... TripAdvisor as the number one best large hotel for families ... world for their annual Travelers’ Choice Awards. , TripAdvisor ... website is home to millions of unbiased and honest traveler ...
(Date:1/22/2015)... January 23, 2015 Angelweddingdress is a famous ... invites its customers to follow it on Facebook, Twitter, and ... Valentine’s Day gift. Angelweddingdress draws a lottery every week. , ... to Feb. 28, 2015. Click Angelweddingdress homepage for ...
(Date:1/22/2015)... Dallas, TX (PRWEB) January 22, 2015 ... the issue of experience and person-centeredness in the long-term ... moving towards action across the continuum. The paper, “The ... the Continuum,” engages perspectives and practices of the patient, ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Joan Lunden, ... keynote speaker at the upcoming 32nd Annual Miami ... Physicians’ Education Resource®, LLC (PER®) , shares that ... have gone undetected if she had not followed up ...
(Date:1/22/2015)... Four years since the release of their debut recording Love ... of Avasa & Matthew Love – the duo are pleased to ... through White Swan Records on February 24, 2015. , THE ROAD ... available to all of us to walk out of the mire ...
Breaking Medicine News(10 mins):Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 3Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4
... Johns Hopkins scientists and their colleagues paired laboratory and epidemiologic ... had a 24 percent lower risk for prostate cancer. ... to use of the drug, or new ones that work ... from the foxglove plant, has been used for centuries in ...
... Using new genetic information, scientists have linked a commonly ... reduced risk of bladder cancer, according to findings presented ... 2-6, and simultaneously published in Cancer Prevention Research, a ... Jian Gu, Ph.D., assistant professor of epidemiology at ...
... SATURDAY, April 2 (HealthDay News) -- Researchers who sequenced ... patients identified more than 1,700 mutations, most of which ... explain why it,s difficult to predict breast cancer patient ... at Washington University in St. Louis and the Siteman ...
... By Jenifer Goodwin HealthDay Reporter , FRIDAY, ... temporarily zaps away forehead wrinkles by freezing the nerves ... The technique, if eventually approved by the U.S. Food ... and Dysport. Both are injectable forms of Botulinum toxin ...
... A new hedgehog pathway inhibitor demonstrated efficacy in ... basal cell nevus syndrome, a rare inheritable disease, according ... Annual Meeting 2011, held April 2-6. In 1996, ... of Oakland Research Institute, and colleagues identified the site ...
... (HealthDay News) -- It,s important to keep injury prevention in ... Greer, of the MCGHealth Sports Medicine Center in Augusta, Ga. ... All children should undergo a physical examination before they participate ... period of time, they should begin increasing their activity ...
Cached Medicine News:Health News:Heart drug cuts prostate cancer risk; holds potential for therapeutic use 2Health News:Heart drug cuts prostate cancer risk; holds potential for therapeutic use 3Health News:Genetic variation linked to longer telomeres and lower risk of bladder cancer 2Health News:Most Breast Tumors Have Unique Genetic 'Fingerprint,' Study Finds 2Health News:Freezing Wrinkles a Possible Alternative to Botox 2Health News:Freezing Wrinkles a Possible Alternative to Botox 3Health News:New inhibitor prevented lesions, reduced tumor size in basal cell cancer 2Health News:New inhibitor prevented lesions, reduced tumor size in basal cell cancer 3Health News:Tips for Keeping Young Athletes Safe 2
... in-vitro diagnostic test kit for the ... in human serum/plasma. This test is ... gelatin particles coated with inactivated Trypanosoma ... are agglutinated in the presence of ...
Elisa test for qualitative detection of Total antibodies to Trypanosoma Cruzi in human serum or plasma....
Sprint Quattro Secure™ is a Steroid-Eluting, True Bipolar, Active Fixation ICD Lead....
The TVL-ADX lead is a thin, high-performing defibrillation lead that offers a true bipolar configuration designed for smarter sensing and low defibrillation threshold for greater patient safety margi...
Medicine Products: